Luminex Co. (NASDAQ:LMNX) declared a special dividend on Wednesday, February 22nd. Shareholders of record on Friday, March 24th will be given a dividend of 0.06 per share on Friday, April 14th. The ex-dividend date is Wednesday, March 22nd.
Luminex (NASDAQ:LMNX) opened at 18.07 on Tuesday. Luminex has a 12-month low of $17.64 and a 12-month high of $23.75. The firm has a 50-day moving average price of $18.67 and a 200-day moving average price of $20.39. The company has a market cap of $739.91 million, a P/E ratio of 56.47 and a beta of 0.59.
Luminex (NASDAQ:LMNX) last announced its quarterly earnings results on Monday, February 6th. The company reported $0.11 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.09 by $0.02. Luminex had a return on equity of 5.53% and a net margin of 5.10%. The business had revenue of $72.30 million for the quarter, compared to the consensus estimate of $70.92 million. During the same period last year, the business posted $0.56 EPS. The business’s revenue was up 19.6% compared to the same quarter last year. On average, analysts forecast that Luminex will post $0.29 earnings per share for the current fiscal year.
LMNX has been the topic of a number of analyst reports. Deutsche Bank AG reiterated a “sell” rating and issued a $18.00 price target on shares of Luminex in a report on Wednesday, January 18th. Jefferies Group LLC reiterated a “hold” rating and issued a $20.00 price target on shares of Luminex in a report on Tuesday, February 14th. Piper Jaffray Companies cut their price target on Luminex from $20.00 to $19.00 and set a “neutral” rating on the stock in a report on Tuesday, February 7th. TheStreet downgraded Luminex from a “b-” rating to a “c+” rating in a report on Wednesday, March 8th. Finally, William Blair reiterated a “market perform” rating on shares of Luminex in a report on Tuesday, February 7th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and one has given a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $21.71.
In related news, Director G Walter Loewenbaum II sold 20,000 shares of the business’s stock in a transaction on Thursday, January 26th. The stock was sold at an average price of $19.75, for a total transaction of $395,000.00. Following the transaction, the director now directly owns 766,240 shares in the company, valued at approximately $15,133,240. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Over the last 90 days, insiders have sold 100,000 shares of company stock worth $2,011,800. 6.90% of the stock is owned by company insiders.
Your IP Address:
Luminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company has a range of instruments using its xMAP technology, including its LUMINEX 100/200 systems offer 100-plex testing; the Company’s FLEXMAP 3D system is its high-throughput, 500-plex testing system, and its MAGPIX system provides 50-plex testing using imaging rather than flow cytometry.
Receive News & Ratings for Luminex Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex Co. and related companies with MarketBeat.com's FREE daily email newsletter.